Q3 2017 Earnings Forecast for Eagle Pharmaceuticals, Inc. Issued By William Blair (EGRX)

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) – Investment analysts at William Blair cut their Q3 2017 earnings per share estimates for Eagle Pharmaceuticals in a research report issued on Thursday. William Blair analyst T. Lugo now expects that the specialty pharmaceutical company will post earnings of $0.57 per share for the quarter, down from their previous estimate of $0.68.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its quarterly earnings data on Monday, May 8th. The specialty pharmaceutical company reported $1.42 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.44 by $0.02. The company had revenue of $76.80 million during the quarter, compared to analyst estimates of $70.10 million. Eagle Pharmaceuticals had a net margin of 44.48% and a return on equity of 79.25%. The firm’s quarterly revenue was up 159.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.06) EPS.

COPYRIGHT VIOLATION WARNING: This story was published by BBNS and is the sole property of of BBNS. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://baseballnewssource.com/markets/q3-2017-earnings-forecast-for-eagle-pharmaceuticals-inc-issued-by-william-blair-egrx-updated-updated-updated/1308397.html.

A number of other research firms have also weighed in on EGRX. Zacks Investment Research lowered Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. Royal Bank Of Canada set a $86.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, April 24th. Piper Jaffray Companies set a $118.00 price objective on Eagle Pharmaceuticals and gave the stock an “overweight” rating in a research report on Tuesday, May 9th. ValuEngine raised Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 16th. Finally, BidaskClub lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 30th. Two analysts have rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $84.00.

Eagle Pharmaceuticals (NASDAQ:EGRX) opened at 50.48 on Friday. The firm has a market cap of $772.24 million, a price-to-earnings ratio of 7.93 and a beta of 1.48. The firm has a 50-day moving average of $74.77 and a 200 day moving average of $77.39. Eagle Pharmaceuticals has a 1-year low of $42.33 and a 1-year high of $97.15.

In other Eagle Pharmaceuticals news, CFO Pete A. Meyers bought 350 shares of the company’s stock in a transaction that occurred on Monday, June 12th. The shares were purchased at an average price of $71.49 per share, with a total value of $25,021.50. Following the completion of the acquisition, the chief financial officer now directly owns 350 shares of the company’s stock, valued at approximately $25,021.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders purchased 805 shares of company stock worth $61,790 in the last three months. 19.50% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. Thrivent Financial for Lutherans increased its position in Eagle Pharmaceuticals by 1.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 4,200 shares of the specialty pharmaceutical company’s stock valued at $333,000 after buying an additional 60 shares in the last quarter. Louisiana State Employees Retirement System increased its position in Eagle Pharmaceuticals by 3.1% in the first quarter. Louisiana State Employees Retirement System now owns 3,300 shares of the specialty pharmaceutical company’s stock valued at $274,000 after buying an additional 100 shares in the last quarter. Arizona State Retirement System increased its position in Eagle Pharmaceuticals by 2.4% in the first quarter. Arizona State Retirement System now owns 4,200 shares of the specialty pharmaceutical company’s stock valued at $348,000 after buying an additional 100 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its position in Eagle Pharmaceuticals by 6.7% in the second quarter. Municipal Employees Retirement System of Michigan now owns 1,910 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 120 shares in the last quarter. Finally, Texas Permanent School Fund increased its position in Eagle Pharmaceuticals by 2.2% in the first quarter. Texas Permanent School Fund now owns 5,867 shares of the specialty pharmaceutical company’s stock valued at $487,000 after buying an additional 125 shares in the last quarter.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Earnings History and Estimates for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Alex Wood Has Shoulder Inflammation
Los Angeles Dodgers Alex Wood Has Shoulder Inflammation
Blues Jays Ready to Take Flight
Blues Jays Ready to Take Flight
Umpires Ending Protest Over Incident With Ian Kinsler
Umpires Ending Protest Over Incident With Ian Kinsler
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Kris Bryant Back in Spotlight, Cubs Pushing for Playoff Berth
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Changes to Reduce The Length of Games, MLB Games are Actually Getting Longer
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts


Leave a Reply

 
© 2006-2017 BBNS.